51. |
52. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysisTanja Čufer, Tudor Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopović, Jacek Jassem, Dragana Jovanovic, Zhasmina MIhaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski, 2020, izvirni znanstveni članek Povzetek: Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making. Ključne besede: non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe Objavljeno v DiRROS: 24.07.2020; Ogledov: 2080; Prenosov: 1177 Celotno besedilo (341,24 KB) Gradivo ima več datotek! Več... |
53. Napotki za premagovanje neželenih učinkov sistemskega zdravljenja raka : kaj morate vedeti?Simona Borštnar, Marjana Bernot, Tanja Čufer, Marika Horvat, Denis Mlakar-Mastnak, Janja Ocvirk, Bojana Pajk, Monika Sonc, Snežana Umičević, Marjetka Uršič-Vrščaj, Metka Zajc, Branko Zakotnik, 2007, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: onkologija Objavljeno v DiRROS: 10.06.2020; Ogledov: 2192; Prenosov: 641 Celotno besedilo (3,72 MB) |
54. |
55. Smernice zdravljenja raka dojkCvetka Bilban-Jakopin, Jožica Červek, Tanja Čufer, Darja Eržen, Rastko Golouh, Kristijana Hertl, Janez Lamovec, Jurij Lindtner, Elga Majdič, Bojana Pajk, Ana Pogačnik, Miljeva Rener, Barbara Vidergar-Kralj, Maja Primic-Žakelj, Janez Žgajnar, 2004, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Objavljeno v DiRROS: 27.05.2020; Ogledov: 2052; Prenosov: 538 Celotno besedilo (904,07 KB) |
56. |
57. |
58. Priporočila za obravnavo bolnikov s pljučnim rakomNina Boc, Martina Vrankar, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But-Hadžić, Anton Crnjac, Eva Ćirić, Tanja Čufer, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik-Kramberger, Maja Ivanetič Pantar, Staša Jelerčič, Veronika Kloboves-Prevodnik, Mile Kovačević, Luka Ležaič, Mateja Marc-Malovrh, Katja Mohorčič, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačić, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar, 2019, strokovna monografija Objavljeno v DiRROS: 24.04.2020; Ogledov: 2715; Prenosov: 884 Celotno besedilo (2,03 MB) |
59. |
60. |